Evidence map›Paper›PMID 16411031›Full record

ArticleQuality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation2006

The relationship between patient knowledge of hemoglobin levels and health-related quality of life.

J Kallich, A McDermott, X Xu, P Fayers, D Cella

Registry-linked trialAbstract read
PubMed Publisher
In one paragraph

Article in Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00540696 (An Open-label, Randomized Study to Develop a Screening Tool for Functional Capacity in Anemic Subjects With Nonmyeloid Malignancies Receiving Chemotherapy and Darbepoetin Alfa), which is not on this map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00540696 phase2completednot on this map

An Open-label, Randomized Study to Develop a Screening Tool for Functional Capacity in Anemic Subjects With Nonmyeloid Malignancies Receiving Chemotherapy and Darbepoetin Alfa (NESP)

TypeinterventionalSponsorAmgenRan2001 to 2003Enrolled300ConditionsAnemia, Non-Myeloid MalignanciesArmsdarbepoetin alfa
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: a meta-analysis.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2009
    Pooled it
  2. Trial
  3. Trial
  4. Darbepoetin alfa impact on health status in diabetes patients with kidney disease: a randomized trial.Clinical journal of the American Society of Nephrology : CJASN · 2011
    Trial
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 2 countries.

J KallichAmgen Inc., Thousand Oaks, CA 91320-1799, USA. jkallich@amgen.com
A McDermott
X Xu
P Fayers
D Cella
Covance (United States) · USAmgen (United States) · USNorthwestern University · USUniversity of Aberdeen · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAn anti-anemia drug may improve self-reported quality of life (QOL) partly because patients know their hemoglobin level is rising. In the absence of any published studies on this topic, the authors investigated the association between knowledge of hemoglobin levels and self-reported QOL.

methodsThe study analyzed health-related QOL (HRQOL) data from five randomized clinical trials of erythropoietic therapy in patients with cancer-related anemia. Patients were asked whether they knew their hemoglobin level and, if so, to report its value. Patients (n=1007) were grouped into three categories depending on the extent and accuracy of hemoglobin level knowledge. HRQOL scale scores were compared between categories.

resultsOnly 23.2% of patients reported knowing their hemoglobin level at the end of the study; however, the value was accurate (within 1 g/dl) in 88.0% of these patients. On five of the 11 HRQOL scales studied, there was a significant association between knowledge of hemoglobin level and HRQOL score. However, the magnitude of the mean difference between those who knew vs. those who did not know their hemoglobin was generally below scale thresholds for minimally important differences.

conclusionsPatient knowledge of hemoglobin level has a modest association with some aspects of self-reported HRQOL. The magnitude of this association, where it exists, would be unlikely to explain large group differences in HRQOL reports over time, even for patients who know their hemoglobin level.

Indexed as

Health Knowledge, Attitudes, PracticeQuality of LifeSickness Impact ProfileAgedAnemiaDarbepoetin alfaEpoetin AlfaErythropoietinFatigueFemaleHematinicsHemoglobinsHumansMaleMiddle AgedNeoplasmsDarbepoetin alfaEpoetin AlfaErythropoietinHematinicsHemoglobinsRecombinant Proteins

Identifiers

PMID16411031
OpenAlexW2077630467

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.